alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 1–20 of 20 studies with an author at Gangnam Severance Hospital (KR) · 27,380 in the whole library · How the 0–100 score works

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Other institutions

From OpenAlex; 12,859 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging

✓ Peer-reviewed alzhub usefulness score 77 out of 100. JAMA neurology 2021-08-01

Among 1431 participants, the mean (SD) age was 71.2 (8.8) years; 751 (52.5%) were male. 2 key findings →

Design: cohort study Participants: 1,135 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Discriminative Accuracy of [18F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders

✓ Peer-reviewed alzhub usefulness score 71 out of 100. JAMA 2018-09-01

In secondary analyses, the area under the curve (AUC) of [18F]flortaucipir SUVR was compared with 3 established magnetic resonance imaging measures (hippocampal volumes and AD signature and whole-brain cortical thickness), and sensitivity and specificity of [18F]flortaucipir in MCI due to AD vs non-AD neurodegenerative disorders were determined. 3 key findings →

Design: cross-sectional Participants: 719 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Tau Positron Emission Tomography for Predicting Dementia in Individuals With Mild Cognitive Impairment

✓ Peer-reviewed alzhub usefulness score 70 out of 100. JAMA neurology 2024-08-01

In the discovery cohort, the mean (SD) age was 70.9 (8.5) years, 191 (58%) were male, the mean (SD) MMSE score was 27.1 (1.9), and 110 individuals with MCI (33%) converted to dementia (71 to AD dementia). 4 key findings →

Design: cohort study Participants: 110 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Assessment of Demographic, Genetic, and Imaging Variables Associated With Brain Resilience and Cognitive Resilience to Pathological Tau in Patients With Alzheimer Disease

✓ Peer-reviewed alzhub usefulness score 67 out of 100. JAMA neurology 2020-05-01

Higher educational level (standardized β = 0.23, P Conclusions and relevance Results of this study suggest that women and young patients with AD have relative preservation of brain structure when exposed to neocortical pathological tau. 3 key findings →

Design: cross-sectional Participants: 260 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Machine Learning-based Individual Assessment of Cortical Atrophy Pattern in Alzheimer's Disease Spectrum: Development of the Classifier and Longitudinal Evaluation

✓ Peer-reviewed alzhub usefulness score 62 out of 100. Scientific reports 2018-03-07

To develop a new method for measuring Alzheimer's disease (AD)-specific similarity of cortical atrophy patterns at the individual-level, we employed an individual-level machine learning algorithm. 5 key findings →

Design: longitudinal study Participants: 473 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Progressive Tau Accumulation in Alzheimer Disease: 2-Year Follow-up Study

✓ Peer-reviewed alzhub usefulness score 59 out of 100. Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2019-03-29

In contrast to no change in global cortical SUVR in the CU- and CU+ groups during the 2-y period, global cortical SUVR increased by 0.06 (2.9%) in the MCI+ group and 0.19 (8.0%) in the DEM+ group at follow-up. 5 key findings →

Design: cross-sectional Participants: 107 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Machine learning prediction of incidence of Alzheimer's disease using large-scale administrative health data

✓ Peer-reviewed alzhub usefulness score 59 out of 100. NPJ digital medicine 2020-03-26

Nationwide population-based cohort provides a new opportunity to build an automated risk prediction model based on individuals' history of health and healthcare beyond existing risk prediction models. 1 key finding →

Participants: 40,736 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Association of Dipeptidyl Peptidase-4 Inhibitor Use and Amyloid Burden in Patients With Diabetes and AD-Related Cognitive Impairment

✓ Peer-reviewed alzhub usefulness score 58 out of 100. Neurology 2021-08-11

These findings suggest that DPP-4i use is associated with low amyloid burden and favorable long-term cognitive outcome in diabetic patients with ADCI. 2 key findings →

Design: longitudinal study Participants: 70 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Anatomical heterogeneity of Alzheimer disease: based on cortical thickness on MRIs

✓ Peer-reviewed alzhub usefulness score 56 out of 100. Neurology 2014-10-24

This cluster analysis of cortical thickness of the entire brain showed that AD dementia in the earlier stages can be categorized into various anatomical subtypes, with distinct clinical features. 5 key findings →

Participants: 52 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Synergistic effects of ischemia and β-amyloid burden on cognitive decline in patients with subcortical vascular mild cognitive impairment

✓ Peer-reviewed alzhub usefulness score 55 out of 100. JAMA psychiatry 2014-04-01

Most patients with svMCI do not exhibit substantial amyloid burden, and CVD does not increase β-amyloid burden as measured by amyloid imaging. 5 key findings →

Design: cross-sectional Participants: 95 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Effect of aspirin use on conversion risk from mild cognitive impairment to Alzheimer’s disease

✓ Peer-reviewed alzhub usefulness score 55 out of 100. Frontiers in Aging Neuroscience 2025-08-06

The data of 508,107 individuals were analyzed (mean [standard deviation] age, 67.6 [10.7] years; 66.8% women and 33.2% men), and 39,318 developed Alzheimer's disease (22,572 controls and 16,746 using aspirin). 5 key findings →

Design: cohort study Participants: 508,107 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Cerebellum Can Serve As a Pseudo-Reference Region in Alzheimer Disease to Detect Neuroinflammation Measured with PET Radioligand Binding to Translocator Protein

✓ Peer-reviewed alzhub usefulness score 51 out of 100. Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2015-03-12

Alzheimer disease (AD) is associated with an increase in the brain of the 18-kDa translocator protein (TSPO), which is overexpressed in activated microglia and reactive astrocytes. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Off-Target 18F-AV-1451 Binding in the Basal Ganglia Correlates with Age-Related Iron Accumulation

✓ Peer-reviewed alzhub usefulness score 48 out of 100. Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2017-08-03

There was an age-related increase in both 18 F-AV-1451 binding in the basal ganglia and R 2 * values in the putamen in both the controls and the Alzheimer disease/mild cognitive impairment patients. 18 F-AV-1451 binding in the basal ganglia increased with R 2 * values. 3 key findings →

Participants: 61 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Plasma p‐tau217 predicts PET‐based pathological staging for precision Alzheimer disease assessment

✓ Peer-reviewed alzhub usefulness score 46 out of 100. Alzheimer s & Dementia 2026-02-01

Plasma p-tau217-based biomarkers showed excellent detecting performance for early amyloid (Thal I-II; area under the curve values > 0.96) and intermediate tau (Braak III-IV; area under the curve values > 0.92). 5 key findings →

Participants: 237 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Virtual reality-based cognitive assessment tools for mild cognitive impairment screening: comparison with traditional paper-and-pencil-based cognitive assessment tools

✓ Peer-reviewed alzhub usefulness score 32 out of 100. Innovation in Aging 2025-12-23

VARABOM.D scores showed significant positive associations with established cognitive assessments. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed